Ullem Scott B., an insider at Edwards Lifesciences Corp (EW), has acquired 47,598 shares of the company at a price of $59.26 per share. The total value of this transaction amounts to $2.82 million and was executed on December 8, 2025. Following this purchase, Ullem holds a total of 47,598 shares in the company.
Edwards Lifesciences, headquartered in Irvine, California, focuses on patient-centric medical innovations for heart disease and critical care monitoring. The company employs approximately 15,800 individuals and trades with a market capitalisation of $48.6 billion. Its product offerings include Transcatheter Aortic Valve Replacement (TAVR) technologies, such as the Edwards SAPIEN 3 systems, and various transcatheter therapies for mitral and tricuspid valves.
This insider transaction highlights a significant investment in the company's stock, which may reflect confidence in its future performance. However, it is important to note that insider buying should not be the sole basis for investment decisions, as various personal or regulatory factors may influence such actions.
Investors are advised to consider broader patterns of insider activity across multiple individuals and timeframes, rather than focusing solely on individual transactions. Edwards Lifesciences is set to report its earnings on April 21, 2026, with an estimated EPS of $0.70 and revenue of $1.6 billion, followed by another report on July 22, 2026, estimating an EPS of $0.75 and revenue of $1.7 billion.